These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 99837)

  • 41. Influence of ethanol and acetaldehyde on fibrinolytic system (examinations in vitro).
    Skrzydlewska E; Worowski K
    Rocz Akad Med Im Juliana Marchlewskiego Bialymst; 1984-1985; 29-30():163-73. PubMed ID: 6242841
    [No Abstract]   [Full Text] [Related]  

  • 42. Inhibition of the plasminogen activator urokinase by alpha-tocopherol.
    Ogston D
    Acta Haematol; 1982; 67(2):114-8. PubMed ID: 6801892
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular heterogeneity of Hageman trait (factor XII deficiency): evidence that two of 49 subjects are cross-reacting material positive (CRM+).
    Saito H; Scott JG; Movat HZ; Scialla SJ
    J Lab Clin Med; 1979 Aug; 94(2):256-65. PubMed ID: 110893
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Liberation of plasminogen activators].
    Klöcking HP; Bock G; Drawert J; Hinsenbrock KP; Kaiser B; Sedlarik U
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1976; 103(3):404-24. PubMed ID: 63428
    [No Abstract]   [Full Text] [Related]  

  • 45. Functional sites of bovine high molecular weight kininogen as a cofactor in kaolin-mediated activation of factor XII (Hageman factor).
    Sugo T; Ikari N; Kato H; Iwanaga S; Fujii S
    Biochemistry; 1980 Jul; 19(14):3215-20. PubMed ID: 7407043
    [No Abstract]   [Full Text] [Related]  

  • 46. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
    Bachmann F
    Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
    Lucore CL; Fujii S; Sobel BE
    Circulation; 1989 Jun; 79(6):1204-13. PubMed ID: 2498004
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Factor XII deficiency - Hageman trait. Additional diagnostic procedures].
    Martinić P
    Bilt Hematol Transfuz; 1979; 7(2-3):151-8. PubMed ID: 263755
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Platelet plasminogen activator inhibitor: purification and characterization of interaction with plasminogen activators and activated protein C.
    Fay WP; Owen WG
    Biochemistry; 1989 Jul; 28(14):5773-8. PubMed ID: 2505842
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Natural inhibitors of fibrinolysis.
    Collen D
    J Clin Pathol Suppl (R Coll Pathol); 1980; 14():24-30. PubMed ID: 6448870
    [No Abstract]   [Full Text] [Related]  

  • 51. Plasminogen activation: biochemistry, physiology, and therapeutics.
    Wun TC
    Crit Rev Biotechnol; 1988; 8(2):131-48. PubMed ID: 2976309
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advances in clinical fibrinolysis.
    Hessel LW; Kluft C
    Clin Haematol; 1986 May; 15(2):443-63. PubMed ID: 2942332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The first component of the kinin-forming system in human and rabbit plasma. Its relationship to clotting factor XII (Hageman Factor).
    Cochrane CG; Wuepper KD
    J Exp Med; 1971 Oct; 134(4):986-1004. PubMed ID: 4106492
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activated protein C increases fibrin clot lysis by neutralization of plasminogen activator inhibitor--no evidence for a cofactor role of protein S.
    de Fouw NJ; de Jong YF; Haverkate F; Bertina RM
    Thromb Haemost; 1988 Oct; 60(2):328-33. PubMed ID: 2975409
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Coagulation and fibrinolysis in rats poisoned with mercuric chloride.
    Michalska M; Mirowski M; Wierzbicki R
    Pol J Pharmacol Pharm; 1988; 40(4):365-71. PubMed ID: 3146750
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of the activation of Hageman factor (factor XII) by platelet factor 4.
    Dumenco LL; Everson B; Culp LA; Ratnoff OD
    J Lab Clin Med; 1988 Sep; 112(3):394-400. PubMed ID: 3045234
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of negatively charged activating compounds on inactivation of factor XIIa by Cl inhibitor.
    Pixley RA; Schmaier A; Colman RW
    Arch Biochem Biophys; 1987 Aug; 256(2):490-8. PubMed ID: 3497611
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit.
    Voss R; Matthias FR; Borkowski G; Reitz D
    Br J Haematol; 1990 May; 75(1):99-105. PubMed ID: 1695855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The "Hageman" connection: interrelationships of blood coagulation, fibrino(geno)lysis, kinin generation, and complement activation.
    Murano G
    Am J Hematol; 1978; 4(4):409-17. PubMed ID: 362910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.